http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20070110852-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
filingDate 2006-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2430a3c2f8091c844ec025d03773901
publicationDate 2007-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20070110852-A
titleOfInvention How to Use Death Receptor Agonists and EVFR Inhibitors
abstract The present invention provides methods of using death receptor ligands such as Apo-2 ligand / TRAIL polypeptide or death receptor antibodies and EGFR inhibitors to treat pathological conditions such as cancer. Embodiments of the present invention include methods of using Apo2L / TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies with EGFR inhibitors such as Tarceva (tradename).
priorityDate 2005-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466647880

Total number of triples: 22.